HRP20120923T1 - Nova kombinacija za upotrebu u lijeäśenju inflamatornih poremeä†aja - Google Patents

Nova kombinacija za upotrebu u lijeäśenju inflamatornih poremeä†aja Download PDF

Info

Publication number
HRP20120923T1
HRP20120923T1 HRP20120923TT HRP20120923T HRP20120923T1 HR P20120923 T1 HRP20120923 T1 HR P20120923T1 HR P20120923T T HRP20120923T T HR P20120923TT HR P20120923 T HRP20120923 T HR P20120923T HR P20120923 T1 HRP20120923 T1 HR P20120923T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
parts
components
Prior art date
Application number
HRP20120923TT
Other languages
English (en)
Croatian (hr)
Inventor
Johan Raud
Original Assignee
Cardoz Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardoz Ab filed Critical Cardoz Ab
Publication of HRP20120923T1 publication Critical patent/HRP20120923T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20120923TT 2006-12-18 2007-11-16 Nova kombinacija za upotrebu u lijeäśenju inflamatornih poremeä†aja HRP20120923T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87537706P 2006-12-18 2006-12-18
US74307P 2007-10-29 2007-10-29
PCT/GB2007/004408 WO2008074975A1 (en) 2006-12-18 2007-11-16 New combination for use in the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
HRP20120923T1 true HRP20120923T1 (hr) 2012-12-31

Family

ID=39135213

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120923TT HRP20120923T1 (hr) 2006-12-18 2007-11-16 Nova kombinacija za upotrebu u lijeäśenju inflamatornih poremeä†aja

Country Status (20)

Country Link
US (1) US20100063070A1 (cg-RX-API-DMAC7.html)
EP (1) EP2120919B1 (cg-RX-API-DMAC7.html)
JP (1) JP2010513430A (cg-RX-API-DMAC7.html)
KR (1) KR20090106526A (cg-RX-API-DMAC7.html)
CN (1) CN101610765A (cg-RX-API-DMAC7.html)
AU (1) AU2007336118A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720358A2 (cg-RX-API-DMAC7.html)
CA (1) CA2672976A1 (cg-RX-API-DMAC7.html)
CY (1) CY1113636T1 (cg-RX-API-DMAC7.html)
DK (1) DK2120919T3 (cg-RX-API-DMAC7.html)
EA (1) EA200900815A1 (cg-RX-API-DMAC7.html)
ES (1) ES2394984T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120923T1 (cg-RX-API-DMAC7.html)
IL (1) IL199214A (cg-RX-API-DMAC7.html)
MX (1) MX2009006507A (cg-RX-API-DMAC7.html)
NO (1) NO20092134L (cg-RX-API-DMAC7.html)
NZ (1) NZ577467A (cg-RX-API-DMAC7.html)
PT (1) PT2120919E (cg-RX-API-DMAC7.html)
SI (1) SI2120919T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008074975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32711A (es) 2009-06-16 2011-01-31 Cardoz Ab Nueva forma cristalina de pemirolast
CA2780382A1 (en) * 2009-11-13 2011-05-19 Cardoz Ab Pemirolast for the treatment of systemic low grade inflammation
CN102302780B (zh) * 2011-09-01 2013-05-01 刘树芹 一种治疗支气管哮喘的药物组合物
CN102389418A (zh) * 2011-09-01 2012-03-28 刘树芹 一种含扎鲁司特和他汀类药物的药物组合物
CN102274515B (zh) * 2011-09-01 2013-04-24 刘树芹 一种含孟鲁司特和他汀类药物的药物组合物
CA3087344A1 (en) 2018-01-05 2019-07-11 Platelet Biogenesis, Inc. Compositions and methods for producing megakaryocytes
JP2021529770A (ja) * 2018-06-29 2021-11-04 プレートレット バイオジェネシス, インコーポレイテッド 薬物送達のための組成物およびその使用方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
WO1995032714A1 (en) * 1994-05-31 1995-12-07 Tokyo Tanabe Company Limited Arteriosclerosis depressant
WO1997045105A1 (en) * 1996-05-24 1997-12-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing diseases of body passageways
US7115278B2 (en) * 1998-04-08 2006-10-03 Theoharis C Theoharides Proteoglycan compositions for the treatment of cardiovascular inflammatory diseases
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US20030235595A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
US6379684B1 (en) * 2001-05-02 2002-04-30 Alphamed Pharaceutical Corp. Cosmetic compositions containing cromolyn compounds for revitalizing the skin
ITMI20011764A1 (it) * 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
JPWO2004002530A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 慢性疾患治療剤
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 HMG−CoAリダクターゼ阻害剤を含有する医薬組成物
JP4588986B2 (ja) * 2002-08-20 2010-12-01 テルモ株式会社 体内埋込医療器具
EP1553075B1 (en) * 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
AU2004305154A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US20060084695A1 (en) * 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2593545A1 (en) * 2005-01-06 2006-07-13 Merck & Co., Inc. Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
NZ560386A (en) * 2005-01-31 2009-12-24 Mylan Lab Inc Pharmaceutical composition comprising hydroxylated nebivolol
US20070225301A1 (en) * 2006-02-13 2007-09-27 Astion Inflammation Aps Treatment of acne and other diseases
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
CA2677493A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions

Also Published As

Publication number Publication date
IL199214A0 (en) 2010-03-28
US20100063070A1 (en) 2010-03-11
EP2120919B1 (en) 2012-08-29
DK2120919T3 (da) 2012-11-26
NZ577467A (en) 2012-04-27
JP2010513430A (ja) 2010-04-30
EA200900815A1 (ru) 2009-12-30
AU2007336118A1 (en) 2008-06-26
KR20090106526A (ko) 2009-10-09
NO20092134L (no) 2009-09-18
IL199214A (en) 2013-04-30
CN101610765A (zh) 2009-12-23
CA2672976A1 (en) 2008-06-26
MX2009006507A (es) 2009-08-18
SI2120919T1 (sl) 2012-12-31
BRPI0720358A2 (pt) 2013-12-24
EP2120919A1 (en) 2009-11-25
HK1134032A1 (en) 2010-04-16
CY1113636T1 (el) 2016-06-22
PT2120919E (pt) 2012-11-12
WO2008074975A1 (en) 2008-06-26
ES2394984T3 (es) 2013-02-07

Similar Documents

Publication Publication Date Title
JP2010513430A5 (cg-RX-API-DMAC7.html)
Storey et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
HRP20170624T1 (hr) Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti
Aggarwal et al. Cardiovascular safety of potential drugs for the treatment of coronavirus disease 2019
MA32354B1 (fr) UTILISATION DE DRONÉDARONE DANS UN MÉDICAMENT UTILISÉ POUR PRÉVENIR UN ÉPISODE CARDIOVASCULAIRE MENANT à L'HOSPITALISATION OU à LA MORT
JP2015518897A5 (cg-RX-API-DMAC7.html)
EP2601958A4 (en) USE OF A SALVIA MILTIORRHIZA COMPOSITION IN THE MANUFACTURE OF MEDICAMENTS FOR THE SECONDARY PREVENTION OF CORONARY HEART DISEASE
EP1961744A4 (en) CONNECTION WITH BASIC GROUPS AND ITS USE
JP2013537903A (ja) カラノライド、その誘導体及び類似体についての医薬組成物並びにそれを製造するための方法
Szadkowska et al. Statin therapy in the elderly: a review
JP2017222722A5 (cg-RX-API-DMAC7.html)
CN109310642A (zh) 美沙拉嗪的口服药物组合物
Hiatt The US experience with cilostazol in treating intermittent claudication
CA3181940A1 (en) Uses and formulations of cannabinoids
Eldin et al. A novel synergistic enzyme-antibiotic therapy with immobilization of mycobacteriophage Lysin B enzyme onto Rif@ UiO-66 nanocomposite for enhanced inhaled anti-TB therapy; Nanoenzybiotics approach
TW201110968A (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
De Luca Low-dose rivaroxaban: can cardiovascular events be reduced?
JP2020502134A5 (cg-RX-API-DMAC7.html)
JP2019511536A5 (cg-RX-API-DMAC7.html)
WO2018154395A3 (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE OF VARENICLINE
Katz et al. Effect of aspirin and ifetroban on skeletal muscle blood flow in patients with congestive heart failure treated with enalapril
JP2016523943A5 (cg-RX-API-DMAC7.html)
CN103948620B (zh) 一种含有山栀苷甲酯的药物组合物及应用
Mercola Integrative cardiovascular disease therapy: Linoleic acid restriction, enhanced external counterpulsation, and emerging nanotherapies
HRP20160358T1 (hr) Polimorfi 6-(piperidin-4-iloksi)-2h-izokinolin-1-on hidroklorida